Description

Piroxicam USP

Piroxicam USP is a long-acting nonsteroidal anti-inflammatory drug (NSAID) used to relieve symptoms of osteoarthritis, rheumatoid arthritis, and other musculoskeletal inflammatory conditions.

• It is a USP-grade active pharmaceutical ingredient (API)
• It inhibits prostaglandin synthesis via COX-1 and COX-2 enzyme blockade
• It is suitable for oral capsules, tablets, and topical formulations
• Its long plasma half-life allows once-daily dosing
• It is manufactured in cGMP-certified facilities
• It is supplied with full regulatory documentation including CoA

Piroxicam exhibits anti-inflammatory, analgesic, and antipyretic activity, making it effective for managing chronic joint disorders and acute musculoskeletal pain. It is particularly valued for its sustained duration of action, which improves patient adherence through reduced dosing frequency.

This API is often formulated into immediate- or controlled-release oral dosage forms and is also studied for transdermal and topical delivery routes. Its physicochemical stability supports diverse formulation approaches in both monotherapy and fixed-dose combination products.

CarboMer provides high-purity Piroxicam USP with consistent lot reproducibility, ideal for developers seeking robust regulatory alignment. The product is tested against USP specifications and undergoes full QC release profiling.

Piroxicam USP MOQ, lead time, and packaging format options are available on request to support R&D, pilot, and commercial-scale needs.

As with all CarboMer APIs, Piroxicam USP is delivered with comprehensive documentation and technical support, ensuring formulators have access to impurity profiles, analytical methods, and regulatory guidance for efficient product development and market approval.